Pharmaceuticals, Biotechnology and Life Sciences
As Vertex expands deal with NHS England to include Kaftrio in combination with Kalydeco, the cysitc fibrosis patients in England will be among the first in Europe to benefit from access to Kaftrio, if the medicine is approved by the European Commission.
Eligible patients in Scotland will immediately have access to ORKAMBI (lumacaftor/ivacaftor) and SYMKEVI (tezacaftor/ivacaftor) in combination with ivacaftor
-Opportunity to treat the underlying cause of CF earlier than ever before- -Safety data from Phase 3 ARRIVAL study support…
Vertex Pharmaceuticals Limitedgot will extend label for its cystic fibrosis children patients treatment Orkambi in Europe, after the Union’s Commissions’ approval.
The European Commission has approved expansion of the indication for Vertex Pharmaceuticals’ Kalydeco, to include children ages 2-5 with cystic fibrosis…